ROLE OF PROBIOTICS IN THE TREATMENT OF HELICOBACTER PYLORIASSOCIATED DISEASES

Download full text PDF
Issue: 
3
Year: 
2015

D. Bordin (1,2), MD; Professor S. Kolbasnikov (2), MD; A. Kononova (2), Candidate of Medical Sciences; I. Voynovan 1 -Moscow Clinical Research and Practical Center, Moscow Healthcare Department 2 -Tver State Medical Academy

The high prevalence and social significance of diseases associated with Helicobacter pylori (Нр), its increased antibiotic resistance, and the lower efficiency of eradication therapy necessitate a search for ways to enhance therapeutic efficiency. One of them is adjuvant probiotic intake that contributes to a reduction in antibiotic-associated adverse reactions and increases adherence to treatment. Lactobacillus reuteri DSMZ 17648 is noted to form specific coaggregates with Hp, and to decrease gastric bacterization, which may promote the higher efficiency of eradication therapy. The possibility of monotherapy with a L. reuteri DSMZ 17648 agent in Hp-infected persons who have no strict indications for eradication is being investigated.
Keywords: 
Helicobacter pylori
eradication therapy
antibiotic resistance
probiotics
Lactobacillus reuteri

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Lazebnik L.B., Vasil'ev Ju.V., Scherbakov P.L. i dr. Helicobacter pylori: rasprostranennost', diagnostika, lechenie // Eksper. i klin. gastroente-rol. – 2010; 2: 3–7
  2. German S.V., Zykova I.E., Modestova A.V. i dr. Rasprostranennost' infektsii N. pylori sredi naselenija Moskvy // Ros. zhurn. gastroenterol., gepatol., koloproktol. – 2010; 2: 25–30.
  3. Baryshnikova N.V., Tkachenko E.I., Uspenskij Ju.P. Sovremennye aspek-3. ty sostojanija problemy Helicobacter pylori-assotsiirovannyh zabolevanij. V kn.:7 Gastroenterologija. Bolezni vzroslyh. Pod obsch. red. L.B. Lazebnika, P.L. Scherbakova / M.: MK, 2011; s. 103.
  4. Tsukanov V.V., Homenko O.V., Rzhavicheva O.S. i dr. Rasprostranennost' 4. Helicobacter pylori i GERB u mongoloidov i evropeoidov vostochnoj Sibiri // Ros. zhurn. gastroenterol., gepatol., koloproktol. –. 2009; 19 (3): 38–41.
  5. Kornienko E.A. Infektsija 5. Helicobacter pylori u detej / M.: GEOTAR-Media, 2011; 276 s.
  6. Reshetnikov O.V., Kurilovich S.A., Krotov S.A. i dr. Helikobakternaja 6. infektsija v sibirskih populjatsijah // Bjull. Sibirskogo otdelenija RAMN. – 2010; 2: 88–93.
  7. Atherton J., Tham K., Peek Jr. R. et al. Density of 7. Helicobacter pylori infection in vivo as assessed by quantitative culture and histology // JID. – 1996; 174: 552–6.
  8. Malfertheiner P., Megraud F., O’Morain C. et al. Management of 8. Helicobacter pylori infection – the Maastricht IV / Florence Consensus Report // Gut. – 2012; 61: 646–64.
  9. Bordin D.S., Bjahov M.Ju., Fedulenkova L.V. Serologicheskaja biopsija» i 9. skrining raka zheludka // Zlokachestvennye opuholi. – 2014; 2 (9): 30–6.
  10. Graham D., Fischbach L. 10. Helicobacter pylori infection // N. Engl. J. Med. – 2010; 363 (6): 595–6.
  11. Delahay R., Rugge M. Pathogenesis of 11. Helicobacter pylori infection // Helicobacter. – 2012; 17 (Suppl. 1): 9–15.
  12. Tkachenko E.I., Baryshnikova N.V., Uspenskij Ju.P. i dr. Helikobakterioz 12. i disbioz zheludochno-kishechnogo trakta: biologicheskie i klinicheskie pro-blemy sosuschestvovanija // Vestnik Sankt-Peterburgskoj gosudarstvennoj akademii im. I.I. Mechnikova. – 2008; 3 (28): 115–20
  13. Lazebnik L.B., Tkachenko E.I., Abdulhakov R.A. i dr. Standarty diagnostiki i lechenija kislotozavisimyh i assotsiirovannyh s Helicobacter pylori zabolevanij (5-e Moskovskoe soglashenie) // Eksper. i klin. gastroen-terol. – 2013; 5: 3–11.
  14. Moiseev S.V. Rol' makrolidov v lechenii infektsij // Klin. farma kol. i ter. – 2003; 12 (2): 33–7.
  15. Sinopal'nikov A.I., Andreeva I.V., Stetsjuk O.U. Bezopasnost' makrolidnyh antibiotikov: kriticheskij analiz // Klin. med. – 2012; 3: 23–9.
  16. Megraud F., Coenen S., Versporten A. et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption // Gut. – 2013; 62 (1): 34–42.
  17. Lazebnik L.B., Belousova N.L., Bordin D.S. i dr. Rezistentnost' Helicobacter pylori k klaritromitsinu v Moskve i propolis kak sredstvo, povy-shajuschee effektivnost' eradikatsii // Eksper. i klin. gastroenterol. – 2012; 8: 10–4.
  18. Osipenko M.F., Bikbulatova E.A., Shakalite Ju.D. i dr. Rezistentnost' 18. Helicobacter pylori k klaritromitsinu v Novosibirske // Eksper. i klin. gastro-enterol. – 2012; 8: 15–7.
  19. Abdulhakov R.A., Abdulhakov S.R., Abuzarova E.R. i dr. Rezistentnost' 19. Helicobacter pylori k klaritromitsinu v Kazani // Eksper. i klin. gastroente-rol. – 2012; 8: 24–9.
  20. Baryshnikova N.V., Denisova E.V., Kornienko E.A. i dr. Epidemiologicheskoe issledovanie rezistentnosti Helicobacter pylori k kla-ritromitsinu u zhitelej Sankt-Peterburga s jazvennoj bolezn'ju // Eksper. i klin. gastroenterol. – 2009; 5: 73–6.
  21. Sablin O.A., Mihajlov N.V., Jurin M.V. i dr. Pervichnaja rezistentnost' Helicobacter pylori k antibiotikam v Sankt-Peterburge // Eksper. i klin. gastroenterol. – 2012; 8: 18–23.
  22. Maev I.V., Samsonov A.A., Golubev N.N. i dr. Helikobakter assotsiirovannaja forma jazvennoj bolezni zheludka i dvenadtsatiperstnoj kishki: problemy terapii // Farmateka. – 2011; 2: 10–7.
  23. Lazebnik L.B., Scherbakov P.L., Bordin D.S. IV Maastrihtskoe soglashenie opublikovano: chto dal'she? // Eksper. i klin. gastroenterol. – 2012; 8: 3–9.
  24. Chernin V.V. Hronicheskij gastrit / Tver': Izdatel'stvo «Triada , 2006; 304 s.
  25. Kornienko E.A. Lechenie infektsii Helicobacter pylori u detej. Metod. posobie dlja vrachej / M.: Biocodex; s. 1–56.
  26. Lesbros-Pantoflickova D., Corthesy-Theulaz I., Blum A. Helicobacter pylori and probiotics // J. Nutr. – 2007; 137 (8): 812–8.
  27. Simanenkov V.I., Suvorov A.N. Rol' probiotikov v probleme eradikatsii H. pylori. V kn.: Disbioz kishechnika. Pod red. E.I. Tkachenko, A.N. Suvorova / SPb, 2007; s. 108–14.
  28. Gotteland M., Poliak L., Cruchet S. et al. Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus in children colonized by Helicobacter pylori // Acta Paediatr. – 2005; 94: 1747–51.
  29. Tsukanov V.V., Amel'chugova O.S., Scherbakov P.L. Sovremennye aspekty eradikatsii N. pylori // Lechaschij vrach. – 2010; 2: 38.
  30. Havkin A.I., Blat S.F. Rol' probioticheskoj terapii pri infektsii Helicobacter pylori u detej // Detskie infektsii. – 2007; 4: 53–8.
  31. Drozdova C.H., Kornienko E.A., Serebrjanaja N.B. Probiotiki kak spsob povyshenija effektivnosti eradikatsii Helicobacter pylori u detej // Ros. med. zhurn. – 2005; 13 (3): 168–70.
  32. Praitano M., Iacono S., Francavilla R. Probiotics and 32. Helicobacter pylori infection // Medicina Universitaria. – 2012; 14: 217–23.
  33. Tong J., Ran Z., Shen J. et al. Meta-analysis: The effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy // Aliment. Pharmacol. Ther. – 2007; 25: 155–68.
  34. Wang Z., Gao Q., Fang J. Meta-analysis of the efficacy and safety of 34. Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy // J. Clin. Gastroenterol. – 2013; 47: 25–32.
  35. Scherbakov P.L., Korsunskij A.A. Helikobakterioz i gastroduodenal'nye zabolevanija u detej / M.: Praktika, 2003.
  36. Kornienko E.A., Drozdova C.H., Serebrjanaja N.B. Probiotiki kak sposob povyshenija effektivnosti eradikatsionnoj terapii. Mat-ly Assamblei «Vrach–provizor–patsient». SPb, 2004; s. 45–7.
  37. Cindoruk M., Erkan G., Karakan T. et al. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double blind stude // Helicobacter. – 2007; 12 (4): 309–16.
  38. Gotteland M., Brunser O., Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? // Aliment. Pharmacol. Ther. – 2006; 23 (10): 1077–86.
  39. Zhao H., Ou-Yang H., Duan B. et al.Clinical effect of triple therapy combined with Saccaromyces boulardii in the treatment of H. pylori infection in children // Chin. J. Cont. Pediatr. – 2014; 16 (3): 230–3.
  40. Szajewska H., Horvath A., Piwowarczyk A. Meta-analisis: the effects of Saccharomyces bolardii supplementation on Helicobacter pylori eradication rates and side effectes during treatment // Aliment. Pharmacol. Ther. – 2010; 32: 1069–79
  41. Nista E., Candelli M., Cremonini F. et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial // Aliment. Pharmacol. Ther. – 2004; 20 (6): 1181–8.
  42. Zou J., Dong J., Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication // Helicobacter. – 2009; 14 (5): 97–107.
  43. Sheu B., Cheng H., Kao A. et al. Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy // Am. J. Clin. Nutr. – 2006; 83: 864–9.
  44. Sykora J., Valeckova K., Amlerova J. et al. Effect of specially designed fermented milk product containing probiotic Lactobacillus casei DN-114001 and the eradication of H. pylori in children // J. Clin. Gastroenterol. – 2005; 39: 692–8.
  45. Usenko D.V. Effektivnost' kislomolochnogo produkta, soderzhaschego L. casei DN-114 001, pri H. rylori-infektsii u detej // Lechaschij vrach. – 2007; 7: 89.
  46. Dehnich N.N., Ivanchik N.V. Lechenie N. pylori-infektsii u detej i pro-biotiki // Pediatrija. – 2014; 2: 41–4
  47. Sachdeva A., Nagpal J. Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: a systematic review and meta-analysis of randomized-controlled trials // Eur. J. Gastroenterol. Hepatol. – 2009; 21 (1): 45–53.
  48. Boonyaritichaikij S. A trial for prophylaxis of H. pylori infection in school children using probiotics. Abstracts of 6th Western Pacific Helicobacter Congress. Bangkok, 2006, p. 9.
  49. Kawai T., Takagi A., Uemura N. et al. Randomized double blind trial of the efficacy of Lactobacillus gasseri OLL2716(LG21) for suppression of Helicobacter pylori // Helicobacter. – 2006; 11 (2): 40.
  50. Gotteland M., Brunser O., Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? // Aliment. Pharmacol. Ther. – 2006; 23: 1077–86.
  51. Zheng X., Lyu L., Mei Z. Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a metanalysis // Rev. Esp. Enferm. Dig. – 2013; 105: 445–53.
  52. Emara M., Mohamed S., Abdel-Aziz H. Lactobacillus reuteri in management of Helicobacter pylori infection in dyspeptic patients: a double-blind placebo-controlled randomized clinical trial // Ther. Adv. Gastroenterol. – 2014; 7 (1): 4–13.
  53. Mehling H., Busjahn A. Non-Viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a New Approach to Helicobacter pylori Control in Humans // Nutrients. – 2013; 5: 3062–73.
  54. Mukai T., Asasaka T., Sato E. et al. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri FEMS // Immunol. Med. Microbiol. – 2002; 32 (2): 105–10.
  55. Holz C., Busjahn A., Mehling H. et al. Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study // Probiotics Antimicrob. Proteins. – 2014 (Epub. a head of print).